Jp Pharma Solutions Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
as on 17-07-2024
- Paid Up Capital ₹ 0.46 Cr
as on 17-07-2024
- Company Age 5 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 18.30 Cr
as on 17-07-2024
- Satisfied Charges ₹ 4.00 Cr
as on 17-07-2024
- Revenue 39.05%
(FY 2022)
- Profit 141.11%
(FY 2022)
- Ebitda 118.55%
(FY 2022)
- Net Worth 45.30%
(FY 2022)
- Total Assets 15.08%
(FY 2022)
About Jp Pharma Solutions
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 0.46 Cr.
The company currently has active open charges totaling ₹18.30 Cr. The company has closed loans amounting to ₹4.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Inderpreet Kaur and Jagpreet Singh serve as directors at the Company.
- CIN/LLPIN
U52609PB2018PTC048606
- Company No.
048606
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Nov 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Mohali, Punjab, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Jp Pharma Solutions?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Inderpreet Kaur  | Director | 01-Nov-2018 | Current |
| Jagpreet Singh | Director | 01-Nov-2018 | Current |
Financial Performance and Corporate Structure Insights of Jp Pharma Solutions.
Jp Pharma Solutions Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 39.05% increase. The company also saw a substantial improvement in profitability, with a 141.11% increase in profit. The company's net worth Soared by an impressive increase of 45.3%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jp Pharma Solutions?
In 2022, Jp Pharma Solutions had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 26 Feb 2024 | ₹9.90 Cr | Open |
Hdfc Bank Limited Creation Date: 29 Jul 2021 | ₹8.40 Cr | Open |
Others Creation Date: 06 May 2019 | ₹4.00 Cr | Satisfied |
How Many Employees Work at Jp Pharma Solutions?
Unlock and access historical data on people associated with Jp Pharma Solutions, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jp Pharma Solutions, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jp Pharma Solutions's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
